Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PGEN - Precigen Inc


IEX Last Trade
1.1
-0.010   -0.909%

Share volume: 556,325
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.11
-0.01
-0.90%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 9%
Liquidity 54%
Performance 3%
Company vs Stock growth
vs
Performance
5 Days
-5.17%
1 Month
-27.63%
3 Months
-17.29%
6 Months
-27.63%
1 Year
-40.54%
2 Year
-50.89%
Key data
Stock price
$1.10
P/E Ratio 
-2.05
DAY RANGE
N/A - N/A
EPS 
-$0.54
52 WEEK RANGE
$0.84 - $1.93
52 WEEK CHANGE
-$0.39
MARKET CAP 
278.039 M
YIELD 
N/A
SHARES OUTSTANDING 
252.763 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$550,324
AVERAGE 30 VOLUME 
$1,306,557
Company detail
CEO: Helen Sabzevari
Region: US
Website: https://www.dna.com/
Employees: 106
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua

Recent news